Tolcapone (BioDeep_00000006636)
Secondary id: BioDeep_00000399159
human metabolite blood metabolite Chemicals and Drugs
代谢物信息卡片
5-(4-methylbenzoyl)-3-nitrobenzene-1,2-diol
化学式: C14H11NO5 (273.0637196)
中文名称: 托卡朋
谱图信息:
最多检出来源 Homo sapiens(blood) 96.43%
分子结构信息
SMILES: CC1=CC=C(C=C1)C(=O)C1=CC(=C(O)C(O)=C1)[N+]([O-])=O
InChI: InChI=1S/C14H11NO5/c1-8-2-4-9(5-3-8)13(17)10-6-11(15(19)20)14(18)12(16)7-10/h2-7,16,18H,1H3
描述信息
Tolcapone is a drug that inhibits the enzyme catechol-O-methyl transferase (COMT). It is used in the treatment of Parkinsons disease as an adjunct to levodopa/carbidopa medication. It is a yellow, odorless, non-hygroscopic, crystalline compound. Tolcapone is associated with a risk of hepatotoxicity. [Wikipedia]
D002491 - Central Nervous System Agents > D018726 - Anti-Dyskinesia Agents > D000978 - Antiparkinson Agents
D004791 - Enzyme Inhibitors > D065098 - Catechol O-Methyltransferase Inhibitors
N - Nervous system > N04 - Anti-parkinson drugs > N04B - Dopaminergic agents
C78272 - Agent Affecting Nervous System > C38149 - Antiparkinsonian Agent
同义名列表
9 个代谢物同义名
5-(4-methylbenzoyl)-3-nitrobenzene-1,2-diol; 4-Methyl-3,4-dihydroxy-5-nitrobenzophenone; 3,4-Dihydroxy-5-nitro-4-methylbenzophenone; 3,4-Dihydroxy-4-methyl-5-nitrobenzophenone; 3,4 Dihydroxy 5 methyl 5 nitrobenzophenone; 3,4-Dihydroxy-5-methyl-5-nitrobenzophenone; Roche brand OF tolcapone; Tolcapone; Tasmar
数据库引用编号
17 个数据库交叉引用编号
- ChEBI: CHEBI:63630
- KEGG: C07949
- KEGGdrug: D00786
- PubChem: 4659569
- HMDB: HMDB0014468
- Metlin: METLIN43355
- DrugBank: DB00323
- ChEMBL: CHEMBL1324
- Wikipedia: Tolcapone
- MeSH: Tolcapone
- chemspider: 3848682
- CAS: 134308-13-7
- PMhub: MS000019707
- PubChem: 10150
- PDB-CCD: TCW
- NIKKAJI: J459.846F
- RefMet: Tolcapone
分类词条
相关代谢途径
Reactome(0)
BioCyc(0)
PlantCyc(0)
代谢反应
1 个相关的代谢反应过程信息。
Reactome(0)
BioCyc(0)
WikiPathways(0)
Plant Reactome(0)
INOH(0)
PlantCyc(0)
PathBank(0)
PharmGKB(0)
1 个相关的物种来源信息
在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：
- PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
- NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
- Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
- Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。
点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。
文献列表
- Joana Rebouta, Luísa Dória, Ana Coelho, Miguel M Fonseca, Guillermo Castilla-Fernández, Nuno M Pires, M A Vieira-Coelho, Ana I Loureiro. HR/MS-based lipidome analysis of rat brain modulated by tolcapone.
Journal of pharmaceutical and biomedical analysis.
2024 Jan; 241(?):115971. doi:
10.1016/j.jpba.2024.115971. [PMID: 38266454] - Luke T Nelson, Ryan J Paxman, Jin Xu, Bill Webb, Evan T Powers, Jeffery W Kelly. Blinded potency comparison of transthyretin kinetic stabilisers by subunit exchange in human plasma.
Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis.
2021 Mar; 28(1):24-29. doi:
10.1080/13506129.2020.1808783. [PMID: 32811187] - Aaro Jalkanen, Veera Lassheikki, Tommi Torsti, Elham Gharib, Marko Lehtonen, Risto O Juvonen. Tissue and interspecies comparison of catechol-O-methyltransferase mediated catalysis of 6-O-methylation of esculetin to scopoletin and its inhibition by entacapone and tolcapone.
Xenobiotica; the fate of foreign compounds in biological systems.
2021 Mar; 51(3):268-278. doi:
10.1080/00498254.2020.1853850. [PMID: 33289420] - Carlos G Moreira, Marta M Morawska, Aron Baumann, Sophie Masneuf, Michael Linnebank, Michael Sommerauer, Hans-Peter Landolt, Daniela Noain, Christian R Baumann. Improved functional and histochemical outcomes in l-DOPA plus tolcapone treated VMAT2-deficient mice.
Neuropharmacology.
2020 12; 181(?):108353. doi:
10.1016/j.neuropharm.2020.108353. [PMID: 33038358] - Valentina Loconte, Michele Cianci, Ilaria Menozzi, Davide Sbravati, Francesco Sansone, Alessandro Casnati, Rodolfo Berni. Interactions of tolcapone analogues as stabilizers of the amyloidogenic protein transthyretin.
Bioorganic chemistry.
2020 10; 103(?):104144. doi:
10.1016/j.bioorg.2020.104144. [PMID: 32791384] - Xin Wang, Murat Cirit, John S Wishnok, Linda G Griffith, Steven R Tannenbaum. Analysis of an Integrated Human Multiorgan Microphysiological System for Combined Tolcapone Metabolism and Brain Metabolomics.
Analytical chemistry.
2019 07; 91(13):8667-8675. doi:
10.1021/acs.analchem.9b02224. [PMID: 31181164] - Shawn Stanley, Koos Van den Berg, Hsiao Ching Foo, Derek Deng. Metabolism and elimination of the catechol-o-methyltransferase inhibitor tolcapone in the horse.
Drug testing and analysis.
2019 Apr; 11(4):578-585. doi:
10.1002/dta.2531. [PMID: 30367738] - Mark Miller, Arindom Pal, Wabel Albusairi, Hyun Joo, Beverly Pappas, Md Tariqul Haque Tuhin, Dengpan Liang, Raghavendra Jampala, Fang Liu, Jared Khan, Marjon Faaij, Miki Park, William Chan, Isabella Graef, Robert Zamboni, Neil Kumar, Jonathan Fox, Uma Sinha, Mamoun Alhamadsheh. Enthalpy-Driven Stabilization of Transthyretin by AG10 Mimics a Naturally Occurring Genetic Variant That Protects from Transthyretin Amyloidosis.
Journal of medicinal chemistry.
2018 09; 61(17):7862-7876. doi:
10.1021/acs.jmedchem.8b00817. [PMID: 30133284] - David Grünig, Andrea Felser, Urs Duthaler, Jamal Bouitbir, Stephan Krähenbühl. Effect of the Catechol-O-Methyltransferase Inhibitors Tolcapone and Entacapone on Fatty Acid Metabolism in HepaRG Cells.
Toxicological sciences : an official journal of the Society of Toxicology.
2018 08; 164(2):477-488. doi:
10.1093/toxsci/kfy101. [PMID: 29688484] - Ghobad Mohammadi, Elahe Faramarzi, Majid Mahmoudi, Sirous Ghobadi, Ali Reza Ghiasvand, Hector C Goicoechea, Ali R Jalalvand. Chemometrics-assisted investigation of interactions of Tasmar with human serum albumin at a glassy carbon disk: Application to electrochemical biosensing of electro-inactive serum albumin.
Journal of pharmaceutical and biomedical analysis.
2018 Jul; 156(?):23-35. doi:
10.1016/j.jpba.2018.04.021. [PMID: 29684908] - Joana Bicker, Ana Fortuna, Gilberto Alves, Patrício Soares-da-Silva, Amílcar Falcão. Elucidation of the Impact of P-glycoprotein and Breast Cancer Resistance Protein on the Brain Distribution of Catechol-O-Methyltransferase Inhibitors.
Drug metabolism and disposition: the biological fate of chemicals.
2017 12; 45(12):1282-1291. doi:
10.1124/dmd.117.077883. [PMID: 28916530] - Xia Lv, Xin-Xin Wang, Jie Hou, Zhong-Ze Fang, Jing-Jing Wu, Yun-Feng Cao, Shu-Wen Liu, Guang-Bo Ge, Ling Yang. Comparison of the inhibitory effects of tolcapone and entacapone against human UDP-glucuronosyltransferases.
Toxicology and applied pharmacology.
2016 06; 301(?):42-9. doi:
10.1016/j.taap.2016.04.009. [PMID: 27089846] - Ricardo Sant'Anna, Pablo Gallego, Lei Z Robinson, Alda Pereira-Henriques, Nelson Ferreira, Francisca Pinheiro, Sebastian Esperante, Irantzu Pallares, Oscar Huertas, Maria Rosário Almeida, Natàlia Reixach, Raul Insa, Adrian Velazquez-Campoy, David Reverter, Núria Reig, Salvador Ventura. Repositioning tolcapone as a potent inhibitor of transthyretin amyloidogenesis and associated cellular toxicity.
Nature communications.
2016 Feb; 7(?):10787. doi:
10.1038/ncomms10787. [PMID: 26902880] - D M Longo, Y Yang, P B Watkins, B A Howell, S Q Siler. Elucidating Differences in the Hepatotoxic Potential of Tolcapone and Entacapone With DILIsym(®), a Mechanistic Model of Drug-Induced Liver Injury.
CPT: pharmacometrics & systems pharmacology.
2016 01; 5(1):31-9. doi:
10.1002/psp4.12053. [PMID: 26844013] - M J Bonifácio, L Torrão, A I Loureiro, P N Palma, L C Wright, P Soares-da-Silva. Pharmacological profile of opicapone, a third-generation nitrocatechol catechol-O-methyl transferase inhibitor, in the rat.
British journal of pharmacology.
2015 Apr; 172(7):1739-52. doi:
10.1111/bph.13020. [PMID: 25409768] - Rômulo Pereira Ribeiro, João Cleverson Gasparetto, Raquel de Oliveira Vilhena, Thais Martins Guimarães de Francisco, Thais Martins Guimarães de Francisco, Cleverson Antônio Ferreira Martins, Marco André Cardoso, Roberto Pontarolo, Katherine Athayde Teixeira de Carvalho. Simultaneous determination of levodopa, carbidopa, entacapone, tolcapone, 3-O-methyldopa and dopamine in human plasma by an HPLC-MS/MS method.
Bioanalysis.
2015; 7(2):207-20. doi:
10.4155/bio.14.230. [PMID: 25587837] - Qu Qi, Lijuan Cao, Feiyan Li, Hong Wang, Huiying Liu, Haiping Hao, Kun Hao. Salvianolic acid B as a substrate and weak catechol-O-methyltransferase inhibitor in rats.
Xenobiotica; the fate of foreign compounds in biological systems.
2015; 45(9):820-7. doi:
10.3109/00498254.2015.1017753. [PMID: 25869243] - Siegfried Muhlack, Lennard Herrmann, Stephan Salmen, Thomas Müller. Fewer fluctuations, higher maximum concentration and better motor response of levodopa with catechol-O-methyltransferase inhibition.
Journal of neural transmission (Vienna, Austria : 1996).
2014 Nov; 121(11):1357-66. doi:
10.1007/s00702-014-1213-3. [PMID: 24770794] - Sarah C Forester, Joshua D Lambert. Synergistic inhibition of lung cancer cell lines by (-)-epigallocatechin-3-gallate in combination with clinically used nitrocatechol inhibitors of catechol-O-methyltransferase.
Carcinogenesis.
2014 Feb; 35(2):365-72. doi:
10.1093/carcin/bgt347. [PMID: 24148818] - Dominika Zajac, Grzegorz Spolnik, Piotr Roszkowski, Witold Danikiewicz, Zbigniew Czarnocki, Mieczyslaw Pokorski. Metabolism of N-acylated-dopamine.
PloS one.
2014; 9(1):e85259. doi:
10.1371/journal.pone.0085259. [PMID: 24465516] - Frida Gustafsson, Alison J Foster, Sunil Sarda, Matthew H Bridgland-Taylor, J Gerry Kenna. A correlation between the in vitro drug toxicity of drugs to cell lines that express human P450s and their propensity to cause liver injury in humans.
Toxicological sciences : an official journal of the Society of Toxicology.
2014 Jan; 137(1):189-211. doi:
10.1093/toxsci/kft223. [PMID: 24085192] - Daphna Laifenfeld, Luping Qiu, Rachel Swiss, Jennifer Park, Michael Macoritto, Yvonne Will, Husam S Younis, Michael Lawton. Utilization of causal reasoning of hepatic gene expression in rats to identify molecular pathways of idiosyncratic drug-induced liver injury.
Toxicological sciences : an official journal of the Society of Toxicology.
2014 Jan; 137(1):234-48. doi:
10.1093/toxsci/kft232. [PMID: 24136188] - Liang Guo, Luke Coyle, Rory M C Abrams, Raymond Kemper, Eric T Chiao, Kyle L Kolaja. Refining the human iPSC-cardiomyocyte arrhythmic risk assessment model.
Toxicological sciences : an official journal of the Society of Toxicology.
2013 Dec; 136(2):581-94. doi:
10.1093/toxsci/kft205. [PMID: 24052561] - Susanne N E Boehn, Sonja Spahn, Sabine Neudecker, Andrea Keppler, Marie-Thérèse Bihoreau, Bettina Kränzlin, Priyanka Pandey, Sigrid C Hoffmann, Li Li, Vicente E Torres, Hermann-Josef Gröne, Norbert Gretz. Inhibition of Comt with tolcapone slows progression of polycystic kidney disease in the more severely affected PKD/Mhm (cy/+) substrain of the Hannover Sprague-Dawley rat.
Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
2013 Aug; 28(8):2045-58. doi:
10.1093/ndt/gft014. [PMID: 23543593] - Daniel J Warner, Hongming Chen, Louis-David Cantin, J Gerry Kenna, Simone Stahl, Clare L Walker, Tobias Noeske. Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
Drug metabolism and disposition: the biological fate of chemicals.
2012 Dec; 40(12):2332-41. doi:
10.1124/dmd.112.047068. [PMID: 22961681] - Robert N McBurney, Wade M Hines, Linda S VonTungeln, Laura K Schnackenberg, Richard D Beger, Carrie L Moland, Tao Han, James C Fuscoe, Ching-Wei Chang, James J Chen, Zhenqiang Su, Xiao-hui Fan, Weida Tong, Shelagh A Booth, Raji Balasubramanian, Paul L Courchesne, Jennifer M Campbell, Armin Graber, Yu Guo, Peter Juhasz, Tricia Y Li, Moira D Lynch, Nicole M Morel, Thomas N Plasterer, Edward J Takach, Chenhui Zeng, Frederick A Beland. The liver toxicity biomarker study phase I: markers for the effects of tolcapone or entacapone.
Toxicologic pathology.
2012 Aug; 40(6):951-64. doi:
10.1177/0192623312444026. [PMID: 22573522] - D Nyholm, A Johansson, H Lennernäs, H Askmark. Levodopa infusion combined with entacapone or tolcapone in Parkinson disease: a pilot trial.
European journal of neurology.
2012 Jun; 19(6):820-6. doi:
10.1111/j.1468-1331.2011.03614.x. [PMID: 22136163] - Lieve Desbonnet, Orna Tighe, Maria Karayiorgou, Joseph A Gogos, John L Waddington, Colm M P O'Tuathaigh. Physiological and behavioural responsivity to stress and anxiogenic stimuli in COMT-deficient mice.
Behavioural brain research.
2012 Mar; 228(2):351-8. doi:
10.1016/j.bbr.2011.12.014. [PMID: 22192380] - Ronald G Robinson, Sean M Smith, Scott E Wolkenberg, Monika Kandebo, Lihang Yao, Christopher R Gibson, Scott T Harrison, Stacey Polsky-Fisher, James C Barrow, Peter J Manley, James J Mulhearn, Kausik K Nanda, Jeffrey W Schubert, B Wesley Trotter, Zhijian Zhao, John M Sanders, Robert F Smith, Debra McLoughlin, Sujata Sharma, Dawn L Hall, Tiffany L Walker, Jennifer L Kershner, Neetesh Bhandari, Pete H Hutson, Nancy A Sachs. Characterization of non-nitrocatechol pan and isoform specific catechol-O-methyltransferase inhibitors and substrates.
ACS chemical neuroscience.
2012 Feb; 3(2):129-40. doi:
10.1021/cn200109w. [PMID: 22860182] - Daniela Gonçalves, Gilberto Alves, Patrício Soares-da-Silva, Amílcar Falcão. Bioanalytical chromatographic methods for the determination of catechol-O-methyltransferase inhibitors in rodents and human samples: a review.
Analytica chimica acta.
2012 Jan; 710(?):17-32. doi:
10.1016/j.aca.2011.10.026. [PMID: 22123108] - Takako Furukawa, Fumihiro Nakamori, Kazuhiro Tetsuka, Yoichi Naritomi, Hiroyuki Moriguchi, Katsuhiro Yamano, Shigeyuki Terashita, Toshio Teramura. Quantitative prediction of intestinal glucuronidation of drugs in rats using in vitro metabolic clearance data.
Drug metabolism and pharmacokinetics.
2012; 27(2):171-80. doi:
10.2133/dmpk.dmpk-11-rg-088. [PMID: 21970858] - Sarah Dawson, Simone Stahl, Nikki Paul, Jane Barber, J Gerald Kenna. In vitro inhibition of the bile salt export pump correlates with risk of cholestatic drug-induced liver injury in humans.
Drug metabolism and disposition: the biological fate of chemicals.
2012 Jan; 40(1):130-8. doi:
10.1124/dmd.111.040758. [PMID: 21965623] - Ching-Wei Chang, Frederick A Beland, Wade M Hines, James C Fuscoe, Tao Han, James J Chen. Identification and categorization of liver toxicity markers induced by a related pair of drugs.
International journal of molecular sciences.
2011; 12(7):4609-24. doi:
10.3390/ijms12074609. [PMID: 21845099] - Angelo Antonini, Daniela Calandrella. Once-daily pramipexole for the treatment of early and advanced idiopathic Parkinson's disease: implications for patients.
Neuropsychiatric disease and treatment.
2011; 7(?):297-302. doi:
10.2147/ndt.s10097. [PMID: 21654875] - Mikael Palner, Patrick McCormick, Jun Parkes, Gitte M Knudsen, Alan A Wilson. Systemic catechol-O-methyl transferase inhibition enables the D1 agonist radiotracer R-[11C]SKF 82957.
Nuclear medicine and biology.
2010 Oct; 37(7):837-43. doi:
10.1016/j.nucmedbio.2010.04.193. [PMID: 20870159] - Paolo Solla, Antonino Cannas, Francesco Marrosu, Maria Giovanna Marrosu. Therapeutic interventions and adjustments in the management of Parkinson disease: role of combined carbidopa/levodopa/entacapone (Stalevo).
Neuropsychiatric disease and treatment.
2010 Sep; 6(?):483-90. doi:
10.2147/ndt.s5190. [PMID: 20856911] - Ki Sung Kang, Yujing Wen, Noriko Yamabe, Masayuki Fukui, Stephanie C Bishop, Bao Ting Zhu. Dual beneficial effects of (-)-epigallocatechin-3-gallate on levodopa methylation and hippocampal neurodegeneration: in vitro and in vivo studies.
PloS one.
2010 Aug; 5(8):e11951. doi:
10.1371/journal.pone.0011951. [PMID: 20700524] - Yoshitatsu Sei, Zhen Li, Jian Song, Renee Ren-Patterson, Elizabeth M Tunbridge, Yukihiko Iizuka, Masahiro Inoue, Berenice T Alfonso, Senda Beltaifa, Yoko Nakai, Bhaskar S Kolachana, Jingshan Chen, Daniel R Weinberger. Epistatic and functional interactions of catechol-o-methyltransferase (COMT) and AKT1 on neuregulin1-ErbB signaling in cell models.
PloS one.
2010 May; 5(5):e10789. doi:
10.1371/journal.pone.0010789. [PMID: 20520724] - Urszula Adamiak, Maria Kaldonska, Gabriela Klodowska-Duda, Elzbieta Wyska, Krzysztof Safranow, Monika Bialecka, Barbara Gawronska-Szklarz. Pharmacokinetic-pharmacodynamic modeling of levodopa in patients with advanced Parkinson disease.
Clinical neuropharmacology.
2010 May; 33(3):135-41. doi:
10.1097/wnf.0b013e3181d47849. [PMID: 20216409] - Maria Luigia De Bonis, Alessandro Tessitore, Maria Teresa Pellecchia, Katia Longo, Anna Salvatore, Antonio Russo, Diego Ingrosso, Vincenzo Zappia, Paolo Barone, Patrizia Galletti, Gioacchino Tedeschi. Impaired transmethylation potential in Parkinson's disease patients treated with L-Dopa.
Neuroscience letters.
2010 Jan; 468(3):287-91. doi:
10.1016/j.neulet.2009.11.014. [PMID: 19909787] - Jinchun Sun, Linda S Von Tungeln, Wade Hines, Richard D Beger. Identification of metabolite profiles of the catechol-O-methyl transferase inhibitor tolcapone in rat urine using LC/MS-based metabonomics analysis.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.
2009 Aug; 877(24):2557-65. doi:
10.1016/j.jchromb.2009.06.033. [PMID: 19615953] - Manthena V S Varma, Bo Feng, R Scott Obach, Matthew D Troutman, Jonathan Chupka, Howard R Miller, Ayman El-Kattan. Physicochemical determinants of human renal clearance.
Journal of medicinal chemistry.
2009 Aug; 52(15):4844-52. doi:
10.1021/jm900403j. [PMID: 19445515] - Muhammad M Nashatizadeh, Kelly E Lyons, Rajesh Pahwa. A review of ropinirole prolonged release in Parkinson's disease.
Clinical interventions in aging.
2009; 4(?):179-86. doi:
10.2147/cia.s3358. [PMID: 19503779] - Robert N McBurney, Wade M Hines, Linda S Von Tungeln, Laura K Schnackenberg, Richard D Beger, Carrie L Moland, Tao Han, James C Fuscoe, Ching-Wei Chang, James J Chen, Zhenqiang Su, Xiao-Hui Fan, Weida Tong, Shelagh A Booth, Raji Balasubramanian, Paul L Courchesne, Jennifer M Campbell, Armin Graber, Yu Guo, Peter J Juhasz, Tricin Y Li, Moira D Lynch, Nicole M Morel, Thomas N Plasterer, Edward J Takach, Chenhui Zeng, Frederick A Beland. The liver toxicity biomarker study: phase I design and preliminary results.
Toxicologic pathology.
2009 Jan; 37(1):52-64. doi:
10.1177/0192623308329287. [PMID: 19171931] - Thomas Müller. Possible treatment concepts for the levodopa-related hyperhomocysteinemia.
Cardiovascular psychiatry and neurology.
2009; 2009(?):969752. doi:
10.1155/2009/969752. [PMID: 20029636] - R Scott Obach, Franco Lombardo, Nigel J Waters. Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals.
2008 Jul; 36(7):1385-405. doi:
10.1124/dmd.108.020479. [PMID: 18426954] - Angelo Antonini, Giovanni Abbruzzese, Paolo Barone, Ubaldo Bonuccelli, Leonardo Lopiano, Marco Onofrj, Mario Zappia, Aldo Quattrone. COMT inhibition with tolcapone in the treatment algorithm of patients with Parkinson's disease (PD): relevance for motor and non-motor features.
Neuropsychiatric disease and treatment.
2008 Feb; 4(1):1-9. doi:
10.2147/ndt.s2404. [PMID: 18728767] - Joseph Jankovic, Mark Stacy. Medical management of levodopa-associated motor complications in patients with Parkinson's disease.
CNS drugs.
2007; 21(8):677-92. doi:
10.2165/00023210-200721080-00005. [PMID: 17630819] - Thomas Müller, Wilfried Kuhn. Tolcapone decreases plasma levels of S-adenosyl-L-homocysteine and homocysteine in treated Parkinson's disease patients.
European journal of clinical pharmacology.
2006 Jun; 62(6):447-50. doi:
10.1007/s00228-006-0132-0. [PMID: 16758261] - Ivelina Gueorguieva, Leon Aarons, Kayode Ogungbenro, Karin M Jorga, Trudy Rodgers, Malcolm Rowland. Optimal design for multivariate response pharmacokinetic models.
Journal of pharmacokinetics and pharmacodynamics.
2006 Apr; 33(2):97-124. doi:
10.1007/s10928-006-9009-1. [PMID: 16550455] - Dag Nyholm. Pharmacokinetic optimisation in the treatment of Parkinson's disease : an update.
Clinical pharmacokinetics.
2006; 45(2):109-36. doi:
10.2165/00003088-200645020-00001. [PMID: 16485914] - Guido Mannaioni, Roberto Baronti, Flavio Moroni. Gastrointestinal bleeding and massive liver damage in neuroleptic malignant syndrome.
Therapeutics and clinical risk management.
2005 Sep; 1(3):225-30. doi:
NULL. [PMID: 18360563] - Nuno Borges. Tolcapone in Parkinson's disease: liver toxicity and clinical efficacy.
Expert opinion on drug safety.
2005 Jan; 4(1):69-73. doi:
10.1517/14740338.4.1.69. [PMID: 15709899] - Shahrzad Tafazoli, Dane D Spehar, Peter J O'Brien. Oxidative stress mediated idiosyncratic drug toxicity.
Drug metabolism reviews.
2005; 37(2):311-25. doi:
10.1081/dmr-55227. [PMID: 15931767] - Katherine L Widnell, Cynthia Comella. Role of COMT inhibitors and dopamine agonists in the treatment of motor fluctuations.
Movement disorders : official journal of the Movement Disorder Society.
2005; 20 Suppl 11(?):S30-7. doi:
10.1002/mds.20461. [PMID: 15822107] - A Gordin, S Kaakkola, H Teräväinen. Clinical advantages of COMT inhibition with entacapone - a review.
Journal of neural transmission (Vienna, Austria : 1996).
2004 Oct; 111(10-11):1343-63. doi:
10.1007/s00702-004-0190-3. [PMID: 15340869] - David J Brooks. Safety and tolerability of COMT inhibitors.
Neurology.
2004 Jan; 62(1 Suppl 1):S39-46. doi:
10.1212/wnl.62.1_suppl_1.s39. [PMID: 14718679] - F Blandini, G Nappi, R Fancellu, A Mangiagalli, A Samuele, G Riboldazzi, D Calandrella, C Pacchetti, G Bono, E Martignoni. Modifications of plasma and platelet levels of L-DOPA and its direct metabolites during treatment with tolcapone or entacapone in patients with Parkinson's disease.
Journal of neural transmission (Vienna, Austria : 1996).
2003 Aug; 110(8):911-22. doi:
10.1007/s00702-003-0004-z. [PMID: 12898346] - Kristiina Haasio, Marko Huotari, Erkki Nissinen, Pekka T Männistö. Tissue histopathology, clinical chemistry and behaviour of adult Comt-gene-disrupted mice.
Journal of applied toxicology : JAT.
2003 Jul; 23(4):213-9. doi:
10.1002/jat.909. [PMID: 12884403] - Nuno Borges. Tolcapone-related liver dysfunction: implications for use in Parkinson's disease therapy.
Drug safety.
2003; 26(11):743-7. doi:
10.2165/00002018-200326110-00001. [PMID: 12908845] - Alessandro Napolitano, Giovanna Bellini, Edilio Borroni, Gerhard Zürcher, Ubaldo Bonuccelli. Effects of peripheral and central catechol-O-methyltransferase inhibition on striatal extracellular levels of dopamine: a microdialysis study in freely moving rats.
Parkinsonism & related disorders.
2003 Jan; 9(3):145-50. doi:
10.1016/s1353-8020(02)00016-0. [PMID: 12573869] - Kristiina Haasio, Anita Koponen, Kai E Penttilä, Erkki Nissinen. Effects of entacapone and tolcapone on mitochondrial membrane potential.
European journal of pharmacology.
2002 Oct; 453(1):21-6. doi:
10.1016/s0014-2999(02)02383-x. [PMID: 12393055] - Claire Henchcliffe, Cheryl Waters. Entacapone in the management of Parkinson's disease.
Expert opinion on pharmacotherapy.
2002 Jul; 3(7):957-63. doi:
10.1517/14656566.3.7.957. [PMID: 12083995] - Roberto Ceravolo, Paola Piccini, Dale L Bailey, Karin M Jorga, Helen Bryson, David J Brooks. 18F-dopa PET evidence that tolcapone acts as a central COMT inhibitor in Parkinson's disease.
Synapse (New York, N.Y.).
2002 Mar; 43(3):201-7. doi:
10.1002/syn.10034. [PMID: 11793426] - M Oechsner, C Buhmann, J Strauss, H J Stuerenburg. COMT-inhibition increases serum levels of dihydroxyphenylacetic acid (DOPAC) in patients with advanced Parkinson's disease.
Journal of neural transmission (Vienna, Austria : 1996).
2002; 109(1):69-75. doi:
10.1007/s702-002-8237-z. [PMID: 11793163] - W Koller, A Lees, M Doder, M Hely. Randomized trial of tolcapone versus pergolide as add-on to levodopa therapy in Parkinson's disease patients with motor fluctuations.
Movement disorders : official journal of the Movement Disorder Society.
2001 Sep; 16(5):858-66. doi:
10.1002/mds.1175. [PMID: 11746615] - M Huotari, M Passlin, H L Nordberg, M Forsberg, S Kotisaari, L Tuomisto, F Shintani, K F Tanaka, I Reenilä, K Laitinen, P T Männistö. Effect of intracerebral 6-nitronoradrenaline, an endogenous catechol-O-methyltransferase (COMT) inhibitor, on striatal dopamine metabolism in anaesthetised rats.
Journal of neuroscience methods.
2001 Aug; 109(1):47-52. doi:
10.1016/s0165-0270(01)00400-9. [PMID: 11489299] - M A Vieira-Coelho, P Gomes, M P Serrão, P Soares-da-Silva. D1-like dopamine receptor activation and natriuresis by nitrocatechol COMT inhibitors.
Kidney international.
2001 May; 59(5):1683-94. doi:
10.1046/j.1523-1755.2001.0590051683.x. [PMID: 11318939] - A Rojo, A Fontán, M A. Mena, A Herranz, S Casado, J G. de Yébenes. Tolcapone increases plasma catecholamine levels in patients with Parkinson's disease.
Parkinsonism & related disorders.
2001 Apr; 7(2):93-96. doi:
10.1016/s1353-8020(00)00027-4. [PMID: 11248589] - H Baas, F Zehrden, R Selzer, R Kohnen, J Loetsch, S Harder. Pharmacokinetic-pharmacodynamic relationship of levodopa with and without tolcapone in patients with Parkinson's disease.
Clinical pharmacokinetics.
2001; 40(5):383-93. doi:
10.2165/00003088-200140050-00005. [PMID: 11432539] - H Keski-Hynnilä, K Raana, J Taskinen, R Kostiainen. Direct analysis of nitrocatechol-type glucuronides in urine by capillary electrophoresis-electrospray ionisation mass spectrometry and tandem mass spectrometry.
Journal of chromatography. B, Biomedical sciences and applications.
2000 Dec; 749(2):253-63. doi:
10.1016/s0378-4347(00)00413-8. [PMID: 11145062] - K S Raevskiĭ, R R Gaĭnetdinov, E A Budygin, P Mannisto, M Wightman. [Pharmacological modulation of dopaminergic transmission in the rat striatum in vivo].
Rossiiskii fiziologicheskii zhurnal imeni I.M. Sechenova.
2000 Sep; 86(9):1152-9. doi:
. [PMID: 11081220] - M Benoit-Marand, M Jaber, F Gonon. Release and elimination of dopamine in vivo in mice lacking the dopamine transporter: functional consequences.
The European journal of neuroscience.
2000 Aug; 12(8):2985-92. doi:
10.1046/j.1460-9568.2000.00155.x. [PMID: 10971639] - K Jorga, L Banken, B Fotteler, P Snell, J L Steimer. Population pharmacokinetics of levodopa in patients with Parkinson's disease treated with tolcapone.
Clinical pharmacology and therapeutics.
2000 Jun; 67(6):610-20. doi:
10.1067/mcp.2000.106795. [PMID: 10872643] - K M Jorga, B Fotteler, R Gasser, L Banken, H Birnboeck. Lack of interaction between tolcapone and tolbutamide in healthy volunteers.
Journal of clinical pharmacology.
2000 May; 40(5):544-51. doi:
10.1177/00912700022009161. [PMID: 10806608] - K M Jorga, T L Davis, M C Kurth, M H Saint-Hilaire, P A LeWitt, B Fotteler, G Zürcher, M Rabbia. Clinical, pharmacokinetic, and pharmacodynamic effects of tolcapone withdrawal in levodopa-treated patients with parkinsonism.
Clinical neuropharmacology.
2000 Mar; 23(2):98-105. doi:
10.1097/00002826-200003000-00007. [PMID: 10803800] - T Müller, D Woitalla, D Schulz, S Peters, W Kuhn, H Przuntek. Tolcapone increases maximum concentration of levodopa.
Journal of neural transmission (Vienna, Austria : 1996).
2000; 107(1):113-9. doi:
10.1007/s007020050010. [PMID: 10809409] - A H Schapira, J A Obeso, C W Olanow. The place of COMT inhibitors in the armamentarium of drugs for the treatment of Parkinson's disease.
Neurology.
2000; 55(11 Suppl 4):S65-8; discussion S69. doi:
NULL. [PMID: 11147512] - C Waters. Practical issues with COMT inhibitors in Parkinson's disease.
Neurology.
2000; 55(11 Suppl 4):S57-9; discussion S60. doi:
NULL. [PMID: 11147511] - K Jorga, B Fotteler, P Heizmann, R Gasser. Metabolism and excretion of tolcapone, a novel inhibitor of catechol-O-methyltransferase.
British journal of clinical pharmacology.
1999 Oct; 48(4):513-20. doi:
10.1046/j.1365-2125.1999.00036.x. [PMID: 10583021] - R Torstenson, J Tedroff, P Hartvig, K J Fasth, B Långström. A comparison of 11C-labeled L-DOPA and L-fluorodopa as positron emission tomography tracers for the presynaptic dopaminergic system.
Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
1999 Oct; 19(10):1142-9. doi:
10.1097/00004647-199910000-00011. [PMID: 10532639] - P Heizmann, M Schmitt, J Leube, H Martin, A Saner. Determination of the catechol-O-methyltransferase inhibitor tolcapone and three of its metabolites in animal and human plasma and urine by reversed-phase high-performance liquid chromatography with ultraviolet detection.
Journal of chromatography. B, Biomedical sciences and applications.
1999 Jul; 730(2):153-60. doi:
10.1016/s0378-4347(99)00146-2. [PMID: 10448949] - K M Jorga, J P Larsen, A Beiske, M Schleimer, B Fotteler, M Schmitt, B Moe. The effect of tolcapone on the pharmacokinetics of benserazide.
European journal of neurology.
1999 Mar; 6(2):211-9. doi:
10.1111/j.1468-1331.1999.tb00015.x. [PMID: 10053234] - J F Horga de la Parte. [Entacapone++ : a new catechol-O-methyltransferase inhibitor which improves the response to levodopa in patients with Parkinson disease and fluctuating motor function].
Revista de neurologia.
1999 Mar; 28(5):499-504. doi:
NULL. [PMID: 10229966] - A Napolitano, P Del Dotto, L Petrozzi, G Dell'Agnello, G Bellini, G Gambaccini, U Bonuccelli. Pharmacokinetics and pharmacodynamics of L-Dopa after acute and 6-week tolcapone administration in patients with Parkinson's disease.
Clinical neuropharmacology.
1999 Jan; 22(1):24-9. doi:
10.1097/00002826-199901000-00005. [PMID: 10047930] - U E Gasser, K Jorga, C Crevoisier, S E Hovens, P L van Giersbergen. COMT inhibition by tolcapone further improves levodopa pharmacokinetics when combined with a dual-release formulation of levodopa/benserazide. A novel principle in the treatment of Parkinson's disease.
European neurology.
1999; 41(4):206-11. doi:
10.1159/000008052. [PMID: 10343151] - K R Larsen, E Z Dajani, N E Dajani, M T Dayton, J G Moore. Effects of tolcapone, a catechol-O-methyltransferase inhibitor, and Sinemet on intestinal electrolyte and fluid transport in conscious dogs.
Digestive diseases and sciences.
1998 Aug; 43(8):1806-13. doi:
10.1023/a:1018852223902. [PMID: 9724173] - R A Hauser, E Molho, H Shale, S Pedder, E E Dorflinger. A pilot evaluation of the tolerability, safety, and efficacy of tolcapone alone and in combination with oral selegiline in untreated Parkinson's disease patients. Tolcapone De Novo Study Group.
Movement disorders : official journal of the Movement Disorder Society.
1998 Jul; 13(4):643-7. doi:
10.1002/mds.870130406. [PMID: 9686768] - K M Jorga, B Fotteler, P Heizmann, G Zürcher. Pharmacokinetics and pharmacodynamics after oral and intravenous administration of tolcapone, a novel adjunct to Parkinson's disease therapy.
European journal of clinical pharmacology.
1998 Jul; 54(5):443-7. doi:
10.1007/s002280050490. [PMID: 9754991] - K M Jorga, J M Kroodsma, B Fotteler, P Heizmann, J Meyer, M C Rasch, J van Hattum. Effect of liver impairment on the pharmacokinetics of tolcapone and its metabolites.
Clinical pharmacology and therapeutics.
1998 Jun; 63(6):646-54. doi:
10.1016/s0009-9236(98)90088-1. [PMID: 9663179] - H Baas, A G Beiske, J Ghika, M Jackson, W H Oertel, W Poewe, G Ransmayr. Catechol-O-methyltransferase inhibition with tolcapone reduces the "wearing off" phenomenon and levodopa requirements in fluctuating parkinsonian patients.
Neurology.
1998 May; 50(5 Suppl 5):S46-53. doi:
10.1212/wnl.50.5_suppl_5.s46. [PMID: 9591522] - K M Jorga. Pharmacokinetics, pharmacodynamics, and tolerability of tolcapone: a review of early studies in volunteers.
Neurology.
1998 May; 50(5 Suppl 5):S31-8. doi:
10.1212/wnl.50.5_suppl_5.s31. [PMID: 9591520] - M C Kurth, C H Adler. COMT inhibition: a new treatment strategy for Parkinson's disease.
Neurology.
1998 May; 50(5 Suppl 5):S3-14. doi:
10.1212/wnl.50.5_suppl_5.s3. [PMID: 9591516] - C G Goetz. Influence of COMT inhibition on levodopa pharmacology and therapy.
Neurology.
1998 May; 50(5 Suppl 5):S26-30. doi:
10.1212/wnl.50.5_suppl_5.s26. [PMID: 9591519] - C De Santi, P C Giulianotti, A Pietrabissa, F Mosca, G M Pacifici. Catechol-O-methyltransferase: variation in enzyme activity and inhibition by entacapone and tolcapone.
European journal of clinical pharmacology.
1998 May; 54(3):215-9. doi:
10.1007/s002280050448. [PMID: 9681662] - K Jorga, B Fotteler, G Sedek, T Nielsen, J Aitken. The effect of tolcapone on levodopa pharmacokinetics is independent of levodopa/carbidopa formulation.
Journal of neurology.
1998 Apr; 245(4):223-30. doi:
10.1007/s004150050209. [PMID: 9591224] - G Sêdek, K Jorga, M Schmitt, R S Burns, P Leese. Effect of tolcapone on plasma levodopa concentrations after coadministration with levodopa/carbidopa to healthy volunteers.
Clinical neuropharmacology.
1997 Dec; 20(6):531-41. doi:
10.1097/00002826-199712000-00005. [PMID: 9403227] - J E Holden, D Doudet, C J Endres, G L Chan, K S Morrison, F J Vingerhoets, B J Snow, B D Pate, V Sossi, K R Buckley, T J Ruth. Graphical analysis of 6-fluoro-L-dopa trapping: effect of inhibition of catechol-O-methyltransferase.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
1997 Oct; 38(10):1568-74. doi:
NULL. [PMID: 9379194] - H Baas, A G Beiske, J Ghika, M Jackson, W H Oertel, W Poewe, G Ransmayr. Catechol-O-methyltransferase inhibition with tolcapone reduces the 'wearing off' phenomenon and levodopa requirements in fluctuating parkinsonian patients.
Journal of neurology, neurosurgery, and psychiatry.
1997 Oct; 63(4):421-8. doi:
10.1136/jnnp.63.4.421. [PMID: 9343116]